- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07943039
Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in Patients With SAA or Hematological Malignancies ( pALG-MSDHSCT )
Safety and Efficacy of Anti-human T-cell Porcine Immunoglobulin in Conditioning Regimens for HLA Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia (SAA)/Hematological Malignancies
This study is a single-arm clinical study designed to evaluate the safety and efficacy of p-ALG in HLA sibling identical Hematopoietic stem cell transplantation( HSCT) conditioning regimens for severe aplastic anemia (SAA)/hematologic malignancies in patients diagnosed with hematologic malignancies or sSAA requiring allogeneic HSCT from our center. Graft anti-host disease (GVHD) is the most common and severe complication of allogeneic HSCT, which significantly affects survival and quality of life. Even among recipients of HLA-identical sibling HSCT (MSD-HSCT), the incidence of acute GVHD( aGVHD) and chronic GVHD (cGVHD) reaches 40-50% and 30-70%, respectively.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study was designed to explore the safety and efficacy of anti-human T cell porcine immunoglobulin p-ALG in the conditioning regimen of HLA sibling allogeneic hematopoietic stem cell transplantation for severe aplastic anemia (SAA)/hematological malignancies in 60 patients.
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.
The enrollment time was 24 months, and patients were followed up for 24 months to evaluate long-term efficacy.
Pharmacokinetics, inflammatory cytokines and active antibodies were measured on day 0 before pALG administration and on days 3, 5, 7, 14, 21, 28 and 60 after p-ALG administration.
Routine follow-up after transplantation was performed to assess implantation and chimerism rate, immune reconstitution, infection prevention, graft versus host disease prevention, treatment-related mortality, and overall survival.
Blood routine, urine routine, liver and kidney function, clinical manifestations and ECOG score were recorded on 28± 7,60 ± 7,90 ± 7,180 ± 7,270 ± 7,360 ± 7,450 ± 7,540 ± 7,630 ± 7,720 ±7 days after transplantation; implantation rate, OS, aGVHD, cGVHD, CMV, EB virus and other infections were recorded.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Erlie Jiang
- Numéro de téléphone: +86-15122538106
- E-mail: jiangerlie@ihcams.ac.cn
Sauvegarde des contacts de l'étude
- Nom: Xin Chen
- Numéro de téléphone: +86-13920985705
- E-mail: chenxin@ihcams.ac.cn
Lieux d'étude
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chine, 300020
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients with severe aplastic anemia (type I/II) or hematologic malignancies undergoing HLA-matched sibling hematopoietic stem cell transplantation.
La description
Inclusion Criteria
- age: no age limit for severe aplastic anemia type I or II, patient or donor age>40 years for hematologic malignancies;
- gender: no gender limit;
- sibling identical hematopoietic stem cell transplantation;
- fair general status, ECOG score <2 points;
- no age limit for severe aplastic anemia, no gender limit; patient or donor age>40 years for hematologic malignancies.
Exclusion Criteria:
- uncontrolled viral, bacterial and fungal infections (disease progression during antifungal therapy);
- pregnant and lactating patients or patients unable to use appropriate contraception during treatment;
- psychiatric disorders or other medical conditions unable to comply with study treatment and monitoring requirements;
- known seropositive for HIV, active hepatitis B, active hepatitis C virus, or syphilis;
- history of tumor and treatment for any tumor within the past 3 years;
- Prior hematopoietic stem cell transplantation;
- Active heart disease, defined as one or more of the following: ① Long QTc syndrome or QTc interval>480ms;② Complete left bundle branch block, degree II or III atrioventricular block;③ History of arrhythmia requiring medication or severe clinical symptoms;④ American New York Heart Association classification ≥II; ④ Left ventricular ejection fraction less than 50%; History of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, history of clinically serious pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to enrollment.
- Subjects considered unsuitable for enrollment by the investigator.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
p-ALG cohort
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days. |
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of acute graft-versus-host disease (aGVHD)
Délai: within 100 days after hematopoietic stem cell infusion
|
aGVHD was evaluated via the modified Glucksberg criteriahematopoietic stem cell transplantation, diagnosed and graded according to standard criteria. |
within 100 days after hematopoietic stem cell infusion
|
|
Incidence of chronic graft-versus-host disease (cGVHD)
Délai: 5 years after hematopoietic stem cell transplantation
|
cGVHD was defined in accordance with the National Institutes of Health (NIH) guidelines |
5 years after hematopoietic stem cell transplantation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
1-year implantation rate
Délai: 1-year
|
The rate of primary and secondary poor engraftment of neutrophils and platelets within 1 year |
1-year
|
|
Overall survival rate
Délai: 5 years after hematopoietic stem cell transplantation
|
All-cause mortality from hematopoietic stem cell infusion to the last follow-up |
5 years after hematopoietic stem cell transplantation
|
|
Rejection (AA) or recurrence (malignant)
Délai: 5 years after hematopoietic stem cell transplantation
|
Rejection (AA) or recurrence (malignant) from hematopoietic stem cell infusion to the last follow-up |
5 years after hematopoietic stem cell transplantation
|
|
Incidence of fungal infection
Délai: 2 years after hematopoietic stem cell infusion
|
Incidence of fungal infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Incidence of cytomegalovirus infection
Délai: 2 years after hematopoietic stem cell infusion
|
Incidence of cytomegalovirus infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Incidence of Epstein-Barr virus infection
Délai: 2 years after hematopoietic stem cell infusion
|
Incidence of Epstein-Barr virus infection from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
|
Transplant-related mortality
Délai: 5 years after hematopoietic stem cell infusion
|
Non-relapse/progression-related death occurring within 100 days after hematopoietic stem cell infusion |
5 years after hematopoietic stem cell infusion
|
|
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last
Délai: 2 years after hematopoietic stem cell infusion
|
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last follow-up |
2 years after hematopoietic stem cell infusion
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IIT2026106
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .